Replies to post #318681 on Innovation Pharmaceuticals Inc (IPIX)

[farrell90]

IMO the human trials will be IV. That is not a big negative as several of the more promising drugs are also IV, eg Remdesivir.

It is possible a long acting depo intramuscular injection could be developed,but I am not aware of any research being done for the IM.

Brilacidin's long half life may mean the IV dosing could be infrequent 1,2 or 3 time may cover a week or two. Brilacidin virucidal MOA may also reduce the need for additional dosing.It is possible 1 IV dose may be adequate, like the ABSSSI trial.

Good luck, Farrell